1. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD.
2. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866.
3. Marino P, Pampallona S, Preatoni A et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients fr om 52 randomised clinical trials. BMJ 1995; 311 (7010): 899–909.
5. Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials J Clin Oncol 2008; 26 (28): 4617–25.
6. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50.
7. Gatzemeier U, Pluzanska A,Szczesna A et al. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545–52.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.
9. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-9.
10. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545–52.
11. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC–CTG]. J Clin Oncol 2007; 25: 1960–6.
12. Davies AM, Ho C, Lara PN Jr et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in nonsmall-cell lung cancer. Clin Lung Cancer 2006; 7: 385–8.
13. Mahaffey CM, Davies AM, Lara PN et al. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer 2007; 8 (9): 548–53.
14. Giovannetti E, Lemos C, Tekle C et al. Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells. Mol Pharmacol 2008; 73: 1290–300.
15. Jimenez U, Gurpide A, Isla D et al. Erlotinib for first line treatment in unselected patients with advanced or metastatic non-small cell lung carcinoma (NSCLC) J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007; 25 (18 Suppl.): 7639.
16. Lilenbaum R, Axelrod R, Thomas S et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008; 26 (6): 863–9.
17. Imyanitov EN, Togo AV, Hanson KP. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett 2004; 204: 3–14. Hamilton M, Wolf J, Rusk J et al. Effects of Smoking on the Pharmacokinetics of Erlotinib. Clin Cancer Res 2006; 12: 2166–71.
18. Toh CK, Wong EH, Lim WT et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: A retrospective analysis. Chest 2004; 126: 1750–6.
19. Nordquist LT, Simon GR, Cantor A et al. Improved survival in never smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004; 126: 347–51.
20. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–51.
21. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306–11.
22. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–46.
23. Blackhall F, Ranson M,Thatcher N. Wh ere next for gefitinib in patients with lung cancer? Lancet Oncol 2006; 7: 499–507.
24. Li J, Zhao M, Hidalgo M et al. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin Cancer Res 2007; 13 (12).
25. Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 2005; 68: 110–8.
26. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50.
27. Patel J, Hensing T, Villafor V et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2007; 25 (18S) Suppl.: 7601.
28. Massarelli E, Andre F, Liu DD et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39: 55–61.
29. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133–44.
30. Shigematsu H, Lin L, Takahashi T et al Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. JNCI Journal of the National Cancer Institute 2005; 97 (5): 339–46.
31. Lecia V Sequist, Renato G et al. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations. J Clin Oncol 2008; 26 (15): 2442–9.
32. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment lung cancer: Reality and hopes. Curr Opin Oncol 2008; 20: 162–75.

А.В.Смолин, А.В.Конев, Т.Г.Соловей, С.Н.Николаева, Ю.Е.Шаманская

Главный военный клинический госпиталь им. Н.Н.Бурденко, Москва